Aviragen Therapeutics Inc Stock Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 08/08 | Vaxart, Inc., Q2 2026 Earnings Call, Aug 07, 2026 | |
| 07/08 | Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 136M 118M 110M 101M 190M 12.97B 193M 1.3B 508M 6.49B 510M 499M 21.66B | P/E 2026 * |
-3.5x | P/E 2027 * | -0.66x |
|---|---|---|---|---|---|
| Enterprise Value | 136M 118M 110M 101M 190M 12.97B 193M 1.3B 508M 6.49B 510M 499M 21.66B | EV / Sales 2026 * |
1.15x | EV / Sales 2027 * | 57.8x |
| Free-Float |
98.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 18/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/03/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 19/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 21/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 04/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 01/01/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.07% | +10.05% | +77.41% | +106.53% | 70.1B | |
| -0.87% | +0.08% | +36.96% | +65.04% | 54.93B | |
| -4.31% | -4.10% | +3.46% | +470.04% | 28.89B | |
| +0.04% | +12.56% | +54.67% | +5.47% | 23.9B | |
| +0.29% | +1.89% | -17.62% | -13.52% | 23.3B | |
| +0.35% | +8.24% | +252.94% | +466.50% | 18.41B | |
| -0.59% | +7.88% | +40.87% | -20.12% | 18.77B | |
| -0.57% | +6.85% | +30.20% | +580.70% | 16.1B | |
| +0.75% | -2.83% | +31.78% | +135.80% | 12.48B | |
| Average | -0.30% | +8.19% | +56.74% | +199.60% | 29.65B | |
| Weighted average by Cap. | -0.08% | +8.03% | +55.30% | +163.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 119M 103M 96.37M 87.87M 165M 11.32B 168M 1.13B 443M 5.67B 445M 436M 18.9B | 2.35M 2.04M 1.91M 1.74M 3.28M 224M 3.33M 22.48M 8.78M 112M 8.82M 8.63M 375M |
| Net income | -47.2M -40.91M -38.35M -34.97M -65.8M -4.5B -66.85M -452M -176M -2.25B -177M -173M -7.52B | -222M -192M -180M -164M -309M -21.15B -314M -2.12B -828M -10.59B -832M -814M -35.31B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
